Výsledky vyhledávání - "Marisa Peluso"

Akademický článek

727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

Autor: Jing Hua, Ricard Masia, Simon Turcotte, John Stagg, Jonathan Hill, Matthew Rausch, Devapregasan Moodley, Marisa Peluso, Secil Koseoglu, Gege Tan, Benjamin Lee, Isabelle Cousineau

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Externí odkaz: https://doaj.org/article/c0e1d5b32e4a47598c694efc312fdced

Zobrazit plný text záznamu

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Autor: Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Sheila Waters, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi

Publikováno v: Clinical Cancer Research. 29:1984-1995

Purpose: Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Hence, we sought

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e1d04de0e092c271491cfd78719407a
https://doi.org/10.1158/1078-0432.ccr-22-2386

Zobrazit plný text záznamu

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Autor: Nicholas Chiorazzi, Kanti R. Rai, Jonathan A. Pachter, David T. Weaver, Sujata Sharma, Marisa Peluso, Jeffery L. Kutok, Sheila Waters, Yasmine Kieso, Michael Ibrahim, Priyadarshini Ravichandran, Yu-Ju Chen, Morgan King-Richards, Gerardo Ferrer, Jacqueline C. Barrientos, Shih-Shih Chen

Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b915f53399d7fc62583f04718343a06
https://doi.org/10.1158/1078-0432.22820110.v1

Zobrazit plný text záznamu

Data from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Purpose:Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Hence, we sought

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c3d6e09a3e1db0191cbb96707dd981d
https://doi.org/10.1158/1078-0432.c.6605170

Zobrazit plný text záznamu

Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

IC50 values of PI3K isoform inhibitors used. Duvelisib5, IPI-3063 (PI3K-d inhibitor)5, IPI-549 (PI3K-g inhibitor used in vitro)50, IPI-5243 (PI3K-g inhibitor used in vivo).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ead5388474787e49d884681dd3bc434
https://doi.org/10.1158/1078-0432.22652506

Zobrazit plný text záznamu

Abstract 4933: Duvelisib eliminates CLL B Cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a patient-derived xenograft model

Autor: Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi

Publikováno v: Cancer Research. 83:4933-4933

Duvelisib (IPI-145), a first-in-class, oral, dual PI3K-δ,γ inhibitor, has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic and follicular lymphoma. Duvelisib potently inhibits PI3K-δ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::beeeae09c6ee024593abe7f007f8fe86
https://doi.org/10.1158/1538-7445.am2023-4933

Zobrazit plný text záznamu

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical Models

Autor: Shih-Shih Chen, Jacqueline Barrientos, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jeff Kutok, Marisa Peluso, Sujata Sharma, David Weaver, Jonathan Pachter, Kanti Rai, Nicholas Chiorazzi

Inhibitors of Bruton’s Tyrosine Kinase (BTKi) and phosphoinositide 3-kinase (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. He

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1385a20f07af2ea0025892daa852548
https://doi.org/10.21203/rs.3.rs-701669/v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání